Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
This study is being done to find out if patient blood samples can be used to perform individualized modeling of cancer therapy-related side effects.
Full description
PRIMARY OBJECTIVES:
I. Generate induced pluripotent stem cells (iPSC's) from patients receiving cancer treatment.
II. Differentiate patient iPSC's into cardiomyocytes and/or neurons or other cell types that may be relevant to modeling cancer therapy-related adverse effects, such as cardiotoxicity and neurotoxicity.
III. Use patient specific iPSC-derived cells to:
IIIa. Model cancer therapy-related toxicities; IIIb. Better understand the mechanisms of toxicities; IIIc. Determine if patient specific genetic variants are causative of toxicities; IIId. Screen novel protective therapies for cancer therapy-related toxicities.
OUTLINE: This is an observational study.
Patients undergo blood sample collection and have their medical records reviewed on study.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Any patient >= 18 years of age
- Previously treated, planned or currently receiving any potentially toxic cancer therapy including but not limited to chemotherapy, targeted and immunotherapies
Exclusion criteria
- Inability on the part of the patient to understand the informed consent or be compliant with the protocol
Trial design
30 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Clinical Trials Referral Office
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal